Loss of
Proteostasis
Misfolded proteins are the substrate of Alzheimer’s, Parkinson’s, and ALS. The proteostasis network — chaperones, proteasome, autophagy — keeps proteins folded correctly. With age, it fails.
The Mechanism
Three failure modes of the proteostasis network
The proteostasis network has three layers of defense. Molecular chaperones(HSP70, HSP90, small HSPs) recognize hydrophobic patches on unfolded proteins and shepherd them to correct folding. When chaperone capacity is exceeded, misfolded proteins are tagged with ubiquitin chains and delivered to the 26S proteasome for degradation. When both fail, selective autophagy (aggrephagy) captures protein aggregates in autophagosomes and degrades them in lysosomes.
With age, all three fail simultaneously. Chaperone expression declines because HSF1 — the master transcription factor for the heat shock response — becomes increasingly suppressed by SIRT1 loss (which itself results from NAD+ decline). Proteasome activity drops ~30% between ages 30 and 70. Autophagy becomes impaired as mTOR is chronically overactivated and AMPK underactivated.
The consequence is protein aggregate accumulation: amyloid-β and tau in neurons (Alzheimer’s), α-synuclein in dopaminergic neurons (Parkinson’s), TDP-43 in motor neurons (ALS), and Lewy bodies across multiple cell types. These aggregates are not merely passive markers of disease — they actively inhibit proteasome function, spread via prion-like mechanisms, and drive neuroinflammation.
Outside the brain, proteostasis failure drives: cataracts (crystallin aggregation), atherosclerosis (oxidized LDL accumulation), and muscle wasting (impaired myosin/actin turnover). Maintaining proteostasis is the upstream intervention for cognitive longevity — and it starts with the redox environment that determines how many proteins oxidize in the first place.
Monitoring
Biomarkers that track proteostasis health
Evidence-Graded Interventions
Proteostasis support with clinical evidence
Tier A = human RCT evidence. Tier B = at least one human trial + mechanistic data.
GlyNAC (Glutathione Restoration)
Tier AGlutathione is the primary defense against protein oxidation. Oxidized proteins misfold and cannot be recognized by chaperones, creating proteostasis backlog. Three Mayo Clinic RCTs (PMIDs: 34129059, 36656670, 35975308) show GlyNAC restores glutathione in older adults and reduces protein carbonylation — the primary oxidative damage marker on proteins.
Sulforaphane (Proteasome Upregulation)
Tier ANRF2 activation by sulforaphane directly upregulates proteasome subunits (PSMA, PSMB) and heat shock proteins (HSP70, HSP90) that refold damaged proteins. It also induces autophagy of protein aggregates via p62/SQSTM1 pathway. Human airway studies confirm NRF2 target gene induction.
R-Alpha Lipoic Acid (R-ALA)
Tier BR-ALA recycles oxidized glutathione back to its active form, extends the functional half-life of intracellular antioxidants, and is a cofactor for pyruvate dehydrogenase — which keeps mitochondria producing ATP for proteasome function. At 10× the potency of α-tocopherol at the inner mitochondrial membrane.
Sauna / Heat Shock Exposure
Tier BAcute heat stress (40–42°C) triggers the heat shock response via HSF1 transcription factor, massively upregulating HSP70, HSP90, and small heat shock proteins. These molecular chaperones refold damaged proteins and tag irreparably misfolded ones for proteasome clearance. Finnish cohort data links regular sauna use to 40% lower all-cause mortality.
Protect cognitive longevity.
Build a proteostasis-targeted protocol: GlyNAC + sulforaphane + heat exposure, mapped to hallmark coverage in real time.